Inovio CEO: Zika Vaccine Could Take a Few Years

The video discusses the rapid development of a DNA-based Zika vaccine by Inovio, highlighting its advantages over traditional methods. It covers the market potential, spread of the virus, and the role of the government in addressing the epidemic. The video also compares Zika to other diseases like Ebola, emphasizing the unique challenges it presents.

What was the timeline for ENOVIA's Zika vaccine development from design to FDA approval for human testing?

• Two years

• Six months

• Three months

• One year

What is a significant advantage of Inovio's DNA-based vaccine technology?

• It uses the whole virus for better immunity.

• It is cheaper to produce than traditional vaccines.

• It avoids using any part of the virus, reducing potential harm.

• It requires fewer doses for effectiveness.

How does Inovio's vaccine technology work?

• By using a live virus to stimulate immunity.

• By using a weakened virus to create antibodies.

• By combining multiple virus strains for broader protection.

• By injecting a non-infectious DNA piece into the subject.

What is a key difference between Zika and Ebola viruses?

• Zika causes immediate death, while Ebola does not.

• Ebola affects the brain, while Zika does not.

• Zika primarily affects neuronal stem cells, unlike Ebola.

• Ebola spreads through mosquitoes, while Zika does not.

What criticism has been directed at the US government regarding the Zika virus?

• Delaying the approval of new vaccines.

• Too much focus on international aid.

• Overreacting to the virus threat.

• Not enough funding for vaccine development.